Clinical Trials
12 trialsNCT03332017 2026-02-18
ROSEWOOD
BeOne Medicines
Phase 2 Completed
NCT03740529 2026-01-27
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Eli Lilly and Company
Phase 1/2 Completed
NCT03105336 2025-12-23
ZUMA-5
Gilead Sciences
Phase 2 Completed
NCT04680052 2025-12-22
InMIND
Incyte Corporation
Phase 3 Active not recruiting
NCT04245839 2025-11-05
TRANSCEND FL
Celgene
Phase 2 Active not recruiting
NCT03568461 2025-10-07
ELARA
Novartis
Phase 2 Completed
NCT05409066 2025-07-28
EPCORE FL-1
Genmab
Phase 3 Active not recruiting
NCT01996865 2025-07-10
MAGNIFY
Celgene
Phase 3 Completed
NCT02631044 2024-06-27
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
Juno Therapeutics, a Subsidiary of Celgene
Phase 1 Completed
NCT01897571 2024-03-26
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL
Ipsen
Phase 1/2 Completed
NCT02204982 2023-09-28
DYNAMO + R
SecuraBio
Phase 3 Terminated
NCT02793583 2022-07-21
UNITY-NHL
TG Therapeutics, Inc.
Phase 2/3 Terminated